BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance – Ortho Spine News
SI-BONE, Inc. (SIBN) reported Q3 2026 revenue of $55.7M, up 14.5% YoY, with U.S. revenue at $52.8M, up 13.9%. Gross margin was 79.3%, net loss improved 20.7% to $3.6M, and adjusted EBITDA turned positive at $3.0M. The company reaffirmed 2026 revenue guidance and reduced operating expense growth expectation to 10.5%.
How this was made
The 30-second read
Why it matters
Quarterly results show revenue growth, narrowing losses, and reaffirmed guidance, which could influence short‑term price action.
Market read
First‑report earnings release with material financial improvements; relevant for traders targeting healthcare devices.
What to watch
Potential reimbursement pressure from new DRG changes could offset growth.
Background
SI-BONE is a Nasdaq‑listed developer of spinal fusion technologies.
Ticker impact
SI-BONE reported Q3 2026 results with revenue up 14.5% YoY, net loss narrowing 20.7% and reaffirmed 2026 guidance.
potential modest upside as market prices in better loss profile and revenue growth
Quarterly loss narrowed and revenue grew, both better than prior year, supporting a bullish bias.
Market effects
Positive earnings may lift other spine‑device and orthopedic stocks.
U.S. healthcare sector could see modest gains.
Limited to medical device niche, no broad market effect.
Counterpoint
If guidance remains unchanged despite modest growth, investors may question upside potential.
Key entities
- ExecutiveLaura Francis
CEO of SI-BONE who commented on the results.
